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Introduction & Objectives
• There is increased risk of thromboembolic events post kidney transplant1
which can often lead to complications such as graft loss2
– These events are associated with both inherited and acquired thrombophilic risk 
factors such as Factor V Leiden mutation3 and antiphospholipid syndrome4
• Many kidney transplant recipients are on anticoagulation or antiplatelet 
therapy for a variety of indications
• These medications may be associated with increased risk of bleeding5, but 
they may also reduce the risk of thrombosis and associated complications6
• There remains a lack of guideline or consensus on perioperative 




– The aim of our study is to review patient and allograft outcomes 
in the context of perioperative anticoagulation or antiplatelet 
therapy in the kidney transplant program at Thomas Jefferson 
University Hospital from 2012-2019.
• Hypothesis
– Patients receiving perioperative anticoagulation or antiplatelet 
therapy will have higher risk of bleeding but lower risk of 
thrombosis and associated allograft loss compared to patients 
not on anticoagulation.
Approach & Results
• Study design: Retrospective chart review
• Population: All patients who underwent kidney or kidney/pancreas 
transplantation at Thomas Jefferson University Hospital from 2012-
2019
• Comparison groups: Patients receiving various forms of 
perioperative anticoagulation or antiplatelet therapy and patients 
not on any such therapy
• Outcomes:
– Bleeding – transfusion utilization, invasive procedures
– Thrombosis – imaging, return to OR
– Graft outcomes
– Graft function – creatinine at 30 days, 90 days, 1 year, 3 years
– Mortality
• Other variables: risk factors for bleeding and thrombosis
• Data source: Epic
Approach & Results
• Data
– We have completed collecting data for the 872 
kidney or kidney/pancreas transplants done at 
TJUH from 2012-2019.
• Analysis
– Not yet complete, a statistician is currently 
working with the data.
Approach & Results
• Hypothesized results:
– Patients on perioperative anticoagulation or 
antiplatelet therapy will have higher rates and 
severity of bleeding, but lower rates of 
thrombosis. 
– Thrombosis episodes will be associated with 
greater allograft loss compared to bleeding 
episodes.
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• Expected: patients on perioperative 
anticoagulation or antiplatelet therapy had higher 
rates and severity of bleeding, but lower rates of 
thrombosis and therefore allograft loss and 
mortality. 
• These results would be generally in line with the 
current literature.
• This study will clarify the outcomes associated 
with perioperative anticoagulation or antiplatelet 
therapy.
Future Directions
• The next step is to use the results of this study 
to develop guidelines for the use of 
perioperative anticoagulation at TJUH.
• This study could be expanded to a larger 
population.
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